OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD

OFI Invest Asset Management decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 196,230 shares of the biopharmaceutical company’s stock after selling 86,817 shares during the period. OFI Invest Asset Management’s holdings in Gilead Sciences were worth $21,756,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of GILD. Southland Equity Partners LLC increased its position in shares of Gilead Sciences by 2.9% during the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 92 shares during the last quarter. Twelve Points Wealth Management LLC grew its holdings in Gilead Sciences by 1.5% in the 2nd quarter. Twelve Points Wealth Management LLC now owns 6,499 shares of the biopharmaceutical company’s stock valued at $721,000 after buying an additional 98 shares in the last quarter. Argentarii LLC lifted its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares during the period. Investment Research & Advisory Group Inc. lifted its position in shares of Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 100 shares during the period. Finally, Lodestar Private Asset Management LLC lifted its position in shares of Gilead Sciences by 3.6% during the 1st quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 100 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on GILD shares. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. Citigroup upped their price objective on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday. Cantor Fitzgerald upped their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Royal Bank Of Canada upped their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.08.

Gilead Sciences Price Performance

Shares of GILD opened at $117.18 on Friday. Gilead Sciences, Inc. has a 12-month low of $84.17 and a 12-month high of $121.83. The business has a 50-day simple moving average of $114.65 and a two-hundred day simple moving average of $110.26. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The stock has a market cap of $145.40 billion, a PE ratio of 23.34, a PEG ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 EPS. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total transaction of $283,925.00. Following the completion of the sale, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 82,000 shares of company stock valued at $9,402,130. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.